Elisa A Rozeman

8PUBLICATIONS
24CO-AUTHORS
Tumour immunologyGene and molecular therapyCellular immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 23, 2024
The emergence of neoadjuvant immune- over BRAF therapy in melanoma.

Elisa A Rozeman, Jason J Luke

|Jul 21, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

Elisa A Rozeman, Judith M Versluis, Karolina Sikorska

|Apr 24, 2023
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.

Esmee P Hoefsmit, Franziska Völlmy, Elisa A Rozeman

|Feb 08, 2023
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

Esmée P Hoefsmit, Paula T van Royen, Disha Rao

|Oct 25, 2019
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

Irene L M Reijers, Elisa A Rozeman, Sofie Wilgenhof

|Aug 20, 2019
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Esmée P Hoefsmit, Elisa A Rozeman, John B A G Haanen

Pageof 2

Frequent Collaborators

4 joint publications

Christian U Blank

4 joint publications

Esmée P Hoefsmit

2 joint publications

John B A G Haanen

2 joint publications

Irene L M Reijers